Abstract:In myeloid malignancies including acute myeloid leukaemia and myelodysplastic syndrome, mutations in spliceosome components drive aberrant RNA splicing and tumourigenesis. Numerous therapeutic strategies have been employed to target this aberrant splicing and achieve splicing‐mutant cell death. Attempted approaches include drugs binding specific spliceosome components, promotion of splicing factor degradation, oligonucleotide therapeutics, and inhibition of splicing factor signalling, methylation, and phosphorylation. Summary In recent years, large‐scale sequencing efforts have identified targetable driver mutations in haematopoietic stem cells. These efforts have led to the development and approval of nine novel agents for relapsed or refractory acute myelogenous leukaemia (R/R AML). However, despite an expansion in targeted therapies, achieving a durable remission in AML and high‐risk myelodysplastic syndrome (HR‐MDS) remains a significant challenge, and there is an urgent need for new effective treatments. Modulation of aberrant RNA splicing has emerged as a novel therapeutic approach in myeloid diseases. Aberrant splicing drives dysregulated gene expression that promotes tumourigenesis through increased proliferation and metastatic potential, immune evasion, decreased apoptosis, and chemotherapy resistance. Mutations in spliceosomal components have been identified in numerous cancer subtypes, with mutations in RNA binding proteins SF3B1, SRSF2, U2AF1, and ZRSR2 occurring frequently in AML and in up to 60% of patients with MDS, as well as in chronic myelomonocytic leukaemia and in 10% of patients with chronic lymphocytic leukaemia. In this review, we explore therapeutic strategies targeting aberrant splicing and the potential of these approaches to drive clinical responses.

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

RNA splicing dysregulation and the hallmarks of cancer

Dysregulation and therapeutic targeting of RNA splicing in cancer

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

Splicing Dysregulation in Cancer: from Mechanistic Understanding to a New Class of Therapeutic Targets

Alternative splicing and cancer: a systematic review

Therapeutic strategies for aberrant splicing in cancer and genetic disorders

RNA Splicing Alterations in Lung Cancer Pathogenesis and Therapy

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Splicing-factor alterations in cancers

Steering research on mRNA splicing in cancer towards clinical translation

The role of alternative pre-mRNA splicing in cancer progression

Aberrant splicing in human cancer: An RNA structural code point of view

Signaling Pathways Driving Aberrant Splicing in Cancer Cells

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

Aberrant pre-mRNA processing in cancer

[Disturbances of alternative splicing in cancer].

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Targeting splicing factors for cancer therapy

Targeting splicing for hematological malignancies therapy